AIM ImmunoTech Inc.
NYSE · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
AIM ImmunoTech is a biopharmaceutical company developing Ampligen, an experimental RNA drug being studied as a treatment for cancer, chronic fatigue syndrome (ME/CFS), and other immune disorders, as well as a potential antiviral agent.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Equels Thomas KCEO & President | Buy | $2K | 11,000at $0.21 | Sep 16, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable AIM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.